DEFA14A: Catheter Precision Seeks Shareholder Approval for Significant Stock Issuances and Reverse Stock Split Ahead of 2025 Annual Meeting

Catheter Precision, Inc. has scheduled its 2025 Annual Meeting of Stockholders to vote on key proposals including the election of a director, the issuance of over 13 million shares, and a reverse stock split.

Summary

• Catheter Precision, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on July 25, 2025, at 11:00 a.m. Eastern Time.
• Shareholders are invited to attend the virtual meeting and vote on six key proposals.
• Proposal 1 involves the election of one Class I director.
• Proposals 2, 3, and 4 seek approval for the issuance of up to 4,285,716 shares upon exercise of Series L Common Stock Purchase Warrants, up to 8,574,000 shares upon conversion of Series B Convertible Preferred Stock, and up to 257,143 shares upon exercise of 2025 Placement Agent Common Stock Purchase Warrants, respectively, totaling up to 13,116,859 new shares.
• Proposal 5 requests approval for an amendment to the company's Certificate of Incorporation to effect a reverse stock split at a ratio between 1-for-5 and 1-for-19, at the Board's discretion, with cash paid for fractional shares.
• Proposal 6 is for the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ended December 31, 2025.
• The Board of Directors recommends a vote FOR all six proposals.

Sentiment

Score: 3

Explanation: The document outlines necessary corporate actions (capital raising mechanisms, listing compliance) but these actions, particularly the reverse stock split and significant potential dilution, often signal underlying challenges or a need for substantial financial restructuring, leading to a generally cautious or negative sentiment.

Positives

• Approval of share issuances could facilitate capital raising through warrant exercises and preferred stock conversions, providing funds for company operations.
• A reverse stock split, if approved and implemented, could help the company maintain compliance with NYSE American listing requirements by increasing its per-share price.
• The ratification of the independent auditor ensures continued financial oversight and compliance.

Negatives

• The potential issuance of up to 13,116,859 new shares represents significant potential dilution for existing common stockholders.
• A reverse stock split, while addressing listing requirements, is often perceived negatively by the market and can sometimes be followed by further stock price declines.
• The need for a reverse stock split suggests the company's stock price has been trading at a low level, potentially indicating underlying financial or operational challenges.

Risks

• Significant shareholder dilution from the exercise of warrants and conversion of preferred stock could negatively impact the value of existing common shares.
• A reverse stock split may not guarantee long-term stock price stability and could lead to reduced liquidity or continued price erosion.
• Failure to approve the reverse stock split could lead to the company's common stock being delisted from the NYSE American if it cannot meet minimum bid price requirements.

Future Outlook

The company is seeking shareholder approval for actions that will significantly impact its capital structure, including potential substantial dilution from new share issuances and a reverse stock split aimed at increasing its stock price, likely to maintain exchange listing compliance. These actions suggest a focus on strengthening the company's financial position and market standing.

Management Comments

• The Board of Directors recommends a vote FOR the nominee listed in Proposal 1, FOR Proposals 2, 3, 4, 5, and 6.

Industry Context

For smaller medical device and healthcare technology companies, particularly those in development or early commercialization stages, capital raises through equity issuances are common to fund research, development, and market expansion. Reverse stock splits are also frequently observed in this sector when companies face challenges maintaining minimum bid price requirements on exchanges like NYSE American, often due to market skepticism or prolonged periods of unprofitability.

Comparison to Industry Standards

• The proposed share issuances are consistent with capital-intensive industries like medical technology, where companies often rely on equity financing to fund innovation and growth, similar to how early-stage biotech firms or other medical device developers raise capital.
• Reverse stock splits are a common mechanism used by companies across various industries, including healthcare, to regain compliance with stock exchange listing rules (e.g., minimum bid price requirements), a strategy employed by companies like Sorrento Therapeutics or Athersys in the past when facing similar challenges.
• The magnitude of potential dilution (over 13 million shares) should be assessed against the company's current outstanding share count and market capitalization to understand its relative impact, which can be significant for smaller companies, potentially exceeding typical capital raise dilutions seen in more mature, larger-cap companies.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential significant dilution from new share issuances, and a change in the number of outstanding shares and per-share price due to the reverse stock split. Fractional shares will be paid in cash.
• Creditors: Potential capital raise through warrant exercises and preferred stock conversion could improve the company's liquidity and financial stability, potentially reducing credit risk.
• Employees: No direct impact mentioned, but improved financial stability could indirectly benefit employees through continued operations and job security.

Next Steps

• Stockholders are encouraged to access and review the complete proxy materials online at www.web.viewproxy.com/VTAK.
• Stockholders must register by 5:00 p.m. Eastern Time on July 24, 2025, to attend the virtual Annual Meeting.
• Stockholders will vote on the six proposals at the Annual Meeting on July 25, 2025.
• If approved, the Board of Directors will proceed with the election of the Class I director, the issuance of shares related to warrants and preferred stock conversion, and the implementation of the reverse stock split at a ratio within the approved range.

Key Dates

Keywords

Catheter Precision, SEC filing, DEFA14A, Proxy Statement, Annual Meeting, Stockholders, Reverse Stock Split, Share Issuance, Warrants, Convertible Preferred Stock, Corporate Governance, NYSE American, Dilution, Medical Devices, Healthcare Technology